Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772889 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 971
- Enrollment target
NCT00772889: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00772889 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 971 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00772889, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 971 participants
- Enrollment target
Study Summary
The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
Primary Outcome
Grade 3 ecchymosis, redness and swelling were ≥ 100 millimeters (mm) and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was \>20 mm for ecchymosis, redness and swelling.
Interventions
- BIOLOGICAL Influenza vaccine GSK2186877A
- BIOLOGICAL GSK Biologicals' Fluarix™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 971 participants |
| Start Date | 2008-10-09 |
| Est. Completion | 2009-12-15 |
| Phase | Phase 3 |
What the finished NCT00772889 record still lists
NCT00772889 is an interventional study that assigns participants to a tested intervention. The registered 971 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 2 interventions - of which Influenza vaccine GSK2186877A is the first listed.
NCT00772889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00772889 about?
NCT00772889 is a clinical study titled "Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly". The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
What is the current status of trial NCT00772889?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 971 participants. The study started on 2008-10-09. Estimated completion is 2009-12-15.
What interventions are being tested in trial NCT00772889?
The interventions under investigation include: Influenza vaccine GSK2186877A (BIOLOGICAL), GSK Biologicals' Fluarix™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT00772889?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00772889's enrollment target sits among peer trials
971 329th of 2000 higher than 1,672 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI